Last updated 7 months ago

Effect of Glp-1 and Antidiabetic sgLT2 Agents for myoCardial infarcTion and Ultrasensitive Inflammatory Surveillance (GALACTUS Trial)

44 patients around the world

Available in Mexico

This is a small open-label pilot clinical trial to assess the effectiveness of dapagliflozin and semaglutide on inflammatory markers (IL-6 and hs-CRP) in patients with STEMI over 24 weeks. It will include patients over 18 years old with STEMI, with or without a diagnosis of type 2 diabetes, clinical obesity, and an initial serum hs-CRP level greater than 2.0 mg/L. Inflammation markers will be measured upon patient admission after percutaneous coronary intervention and again after 24 weeks of treatment with the drugs. Patients will be discharged in accordance with STEMI treatment guidelines, and their medication adherence and tolerability will be monitored.

Instituto Mexicano del Seguro Social

44Patients around the world

This study is for people with

Coronary heart disease

Acute myocardial infarction

Requirements for the patient

From 18 Years

All Gender

Medical requirements

: Criteria for the fourth definition of acute myocardial infarction with ST-segment elevation.
Diagnosed with type 2 diabetes.
Initial serum high-sensitivity CRP value > 2.0 mg/L.
Clinically obese.
LVEF >50%.

: Patients who have recently received immunosuppressive therapy.
Patients with a history of ischemic heart disease.
Known allergy to any of the medications used.
Use of any of the study drugs more than 6 months prior to randomization.
Patients experiencing diabetic ketoacidosis.
Patients with hemodynamic instability (mean arterial pressure <60 mmHg while on vasopressors).
Pregnant women.
Patients with a history or current diagnosis of cancer.
Patients with documented active infections, such as pneumonia or urinary tract infections.
Patients with pancreatitis.

StudyGALACTUS

SponsorInstituto Mexicano del Seguro Social

Study typeInterventional

Conditions

Acute myocardial infarction

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07295223